Navigation Links
SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
Date:8/7/2009

r $168,395, to $2.1 million for the six months ended June 30, 2009, compared to $2.3 million for the same period in 2008. These decreases were primarily due to a decrease in personnel related expenses through personnel reductions, a decrease in travel expenses, and a reduction in insurance premium expense. These decreases were offset by an increase in outside services related to investment banking activities and an increase in legal expenses.

Other income decreased 98%, or $55,774 to $958 for the three months ended June 30, 2009, compared to $56,732 for the comparable period in 2008 and decreased 95%, or $145,137 to $7,600 for the six months ended June 30, 2009, compared to $152,737 for the same period in 2008. These decreases were due to a decrease in interest income due to lower cash balances.

Net loss decreased 26%, or $540,603 to $1.6 million for the three months ended June 30, 2009, compared to $2.1 million for the same period in 2008 and the net loss for the six months ended June 30, 2009, decreased 15%, or $628,477 to $3.5 million, compared with a net loss of $4.1 million for the same period in 2008. These decreases were primarily due to lower operating expenses offset by lower revenues.

Liquidity and Capital Resources

We had approximately $3.1 million in cash and cash equivalents, and $473,711 in restricted cash as of June 30, 2009. Based on our current operating plan, we anticipate that our existing cash and cash equivalents, together with expected royalties from third parties, will fund our operations until late 2009, assuming we do not trigger additional obligations, including contractual severance or lease obligations and unless unforeseen events arise that negatively impact our liquidity. In the event we are unsuccessful generating additional revenues or raising additional funds, we will have to substantially reduce our operations to preserve capital or seek ban
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
2. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
3. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
5. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
6. ULURU Discussions to Acquire York Pharma, plc Are Currently Terminated
7. CutisPharma, Inc. Receives Verified Accreditation for Wholesale Distributors from the National Association of Boards of Pharmacy for Woburn Facility
8. Strativas Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA
9. Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis
10. Sinobiopharma, Inc. Appoints New Director of Marketing
11. Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 July 30, 2014. ... a biotechnology firm that provides DNA-based authentication and security ... Ph.D. Vice President of Life Sciences, a newly created ... , Dr. Hogan will lead APDN’s drive to build ... with biotech and healthcare customers, provide guidance to APDN’s ...
(Date:7/30/2014)... , July 30, 2014  Dyadic International, Inc. ... whose patented and proprietary technologies are used to ... proteins for the bioenergy, bio-based chemical, biopharmaceutical and ... Thomas "Tom" Dubinski as Vice President and Chief ... the financial and information technology operations for Dyadic ...
(Date:7/30/2014)... Edwardsville, IL (PRWEB) July 30, 2014 ... Dr. Arun Athmanathan will present his findings on ... of Energy conference this week in Washington, D.C. ... Department of Energy conference is a testament to ... Director John Caupert said. “Thanks to the foresight ...
(Date:7/30/2014)... 30, 2014 LayerBio, Inc., an MIT ... its first round of seed financing from friends and ... efforts to develop a novel sustained-release product for ophthalmology. ... investors and their commitment to this important work," said ... is one of many areas in which innovations in ...
Breaking Biology Technology:Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
... , VANCOUVER , July 28 ... ANP) ("Angiotech") and partner Athersys, Inc. (NASDAQ: ATHX) ... trial of MultiStem(R), its allogeneic cell therapy product, ... more commonly referred to as a heart attack. ...
... July 28 VIASPACE Inc. (OTC Bulletin Board: ... a low-carbon, renewable biomass crop, reported that Chief Executive Dr. ... Third Annual World Congress of Industrial Biotechnology held in ... than 500 business executives, industry leaders, technical experts, government officials ...
... July 27 ITelagen, a leading provider of electronic health record ... Asthma Associates of Northern California , San Jose, CA ... includes hosting of patient data in ITelagen,s SAS-70 Type II certified datacenter ... , , ...
Cached Biology Technology:Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 2Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 3Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 4Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 5Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 6Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 7Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 8Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 9VIASPACE CEO Discusses Giant King Grass at Industrial Biotechnology Congress in China 2VIASPACE CEO Discusses Giant King Grass at Industrial Biotechnology Congress in China 3VIASPACE CEO Discusses Giant King Grass at Industrial Biotechnology Congress in China 4Allergy and Asthma Associates Selects ITelagen for Hosting and Management of EHR 2Allergy and Asthma Associates Selects ITelagen for Hosting and Management of EHR 3
(Date:7/30/2014)... Everybody knows the shortest distance between two points is ... that sperm have been taking the familiar axiom to ... usually thought to be intense, with each racing for ... in some species, sperm form cooperative groups that allow ... , A new study, conducted by Heidi Fisher, ...
(Date:7/30/2014)... Sciences Institute (SALSI), a joint venture between The University ... of Texas Health Science Center at San Antonio, has ... The winners, Emily Boice from UTSA and Lei Huang ... their project titled, "Novel engineered ferritins for tracking and ... and Huang,s research is focused on finding a treatment ...
(Date:7/30/2014)... Laboratory has received a pledge of $1 million from ... the Laboratory,s new Neurobehavioral Biometry Center. , ... will enable the Laboratory to develop a greater breadth ... ultimate goal of accelerating the pace of research to ... as a premier resource for the Laboratory and its ...
Breaking Biology News(10 mins):When cooperation counts 2When cooperation counts 3Rossi Foundation pledges $1M for JAX neurobehavioral research center 2
... Hopkins researchers say they have discovered a cause-and-effect ... schizophrenia previously believed to be independent of one ... to develop better drugs to treat the cognitive ... illnesses. ,Researchers have long studied the role ...
... 2012 The University of Miami (UM) Rosenstiel School of ... 2012-2013 Alumni Awards. The grantees were selected by a ... more than $11,000 in funds. , "We received 30 applications ... biology to meteorology," said Laura Bracken Chaibongsai, Alumni & Outreach ...
... place certain types of living cells on a microscope slide, ... and assemble themselves into a simple, if primitive tissue. A ... and then some, about the mechanical structure and behavior of ... Proceedings of the National Academy of Sciences , chemical ...
Cached Biology News:Johns Hopkins researchers link 2 biological risk factors for schizophrenia 2Recipients of UM Rosenstiel School's 2012-2013 Alumni Awards announced 2Force of nature: Defining the mechanical mechanisms in living cells 2Force of nature: Defining the mechanical mechanisms in living cells 3Force of nature: Defining the mechanical mechanisms in living cells 4
... Silver Staining Kit, 1. Select from ... and peptides on denaturing, native, and ... reproducibility with precast gels, buffer strips, ... to that of radioisotopes with ready-to-use ...
Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
... Anti-Major DNA-binding protein(DBP). Protein ... NP_001343 ELISA titre using ... Suggested conditions for Western Blot: ... buffer, and HRP conjugated anti-Rabbit IgG should ...
... GI Number: 4503277 Accession Number: ... FUNCTION: Supplies the nucleotide substrate for ... H 2 O = dUMP + ... Belongs to the Diseases: Benign Tumor; ...
Biology Products: